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Abstract
Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiomyopathy. The identification of
patients with HCM is sometimes still a challenge. Moreover, the pathophysiology of the disease is complex
because of left ventricular hyper-contractile state, diastolic dysfunction, ischemia and obstruction which can be
coexistent in the same patient. In this review, we discuss the current and emerging echocardiographic methodol-
ogy that can help physicians in the correct diagnostic and pathophysiological assessment of patients with HCM.
Introduction
Hypertrophic cardiomyopathy (HCM) is clinically defined
in presence of left ventricular (LV) hypertrophy in the
absence of hypertension and valve disease. LV hypertrophy
without cardiovascular causes occurs in approximately
1:500 of the general population [1-3]. This incidence
includes all kinds of hypertrophy not necessarily HCM,
which is a familial disease with an autosomal dominant
pattern of inheritance caused by mutations in genes
encoding for sarcomeric proteins resulting usually in an
asymmetrical pattern of LV hypertrophy. Echocardiogra-
phy plays a pivotal role in detecting the disease and under-
standing its pathophysiology. In this review, we discuss the
current and emerging echocardiographic methodology
that can help physician in the correct diagnosis and patho-
physiological assessment of patients with HCM.
Echocardiography and Diagnosis
Conventional Echocardiography
HCM may be initially suspected because of an heart
murmur, positive family history, new symptoms or
abnormal ECG pattern showing LV hypertrophy and
abnormal Q waves. Thereafter an echocardiogram is
usually performed.
M-Mode Echocardiography
The first echocardiographic diagnostic criteria in HCM
were established by using M-mode imaging which
included asymmetrical septal hypertrophy, systolic ante-
rior motion of the mitral valve (SAM), a small LV cav-
ity, septal immobility, and premature closure of the
aortic valve [1-3]. LV thickness, evaluated at septum and
free wall level, is considered abnormal when ≥ 15 mm,
and defined asymmetrical in presence of a septal to free
wall thickness ratio between 1.3 and 1.5. SAM is charac-
terized by an abrupt anterior movement of the mitral
valve reaching its peak before maximum movement of
the posterior wall (Figure 1); this characteristic allows to
differentiate true SAM from SAM produced by an exag-
gerated anterior motion of the mitral valve which
reaches its peak after the fully contraction of the poster-
ior wall, i.e. “pseudo SAM” [4]. There is a positive corre-
lation between the severity of SAM and the severity of
obstruction evaluated invasively [5]. Usually, a contact
between SAM and the septum indicates an obstruction
≥30 mmHg. Moreover, the measurement of the time
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interval from the beginning of SAM to the SAM-septal
contact (y) and the duration of SAM-septal contact (x)
provides a reliable non-invasive method for estimation
of the pressure gradient, where the gradient is (x/y)*25
+25 mmHg (Figure 1) [5].
The movement of mitral valve is easily visualized by
M-Mode and its anterior motion during systole,
together with asymmetrical septal hypertrophy, was
initially thought to be pathognomonic of HCM. How-
ever, these findings may be present in other forms of
secondary and primary hypertrophy, like chronic sys-
temic and reno-vascular hypertension [6], Fabry’s dis-
ease [7,8], glicogenosis [9], Friedreich ataxia [10], etc.
Left atrial (LA) diameter is usually increased in
patients with HCM because of obstruction and/or dia-
stolic dysfunction. LA diameter gives informations about
the risk of atrial fibrillation, of heart failure development
and of cardiac mortality [11] which is particularly high
in patients with a LA diameter > 48 mm. Finally, LA
fractional shortening, evaluated as ([maximal diameter-
minimum diameter]/maximal diameter*100), is an esti-
mate of end-diastolic pressure in HCM [12]; this
parameter is directly related to exercise tolerance [13],
and its reduction (i.e.<16%) represents an independent
risk factor for atrial fibrillation development [14].
Two-dimensional echocardiography
This technique by visualizing the whole heart has come
the recognition that LV hypertrophy is most often asym-
metrical and it can be confined in specific LV segments
such as the apex.
LV hypertrophy and function
Currently, using short-axis view the left ventricle is
divided in 4 LV wall segments: anterior and posterior
septum and posterior and lateral wall (Figure 2, left
panel) [4]. Segments are visualized at mitral and papil-
lary level, whereas the possible extension to the apex is
visualized by 4 chamber view (Figure 2, right panel).
Classical LV hypertrophy cut-off suggestive of HCM in
the general adult population is 15 mm [15]. Usually the
pattern of LV hypertrophy is asymmetrical, with the
anterior septum involved in the majority of cases being
also the site of the maximal LV hypertrophy in most
patients (Figure 3). In almost 40% of patients, LV hyper-
trophy involves two segments, whereas the concentric
pattern or hypertrophy confined to the apex are particu-
larly uncommon in Western countries (1% each) [16].
Recently, it has been demonstrated [17] that mutations
in the alpha-cardiac actin gene can express apical HCM
or LV non compaction or septal defects. Nevertheless,
LV non compaction has to be differentiated from the
apical form of HCM (Figure 4).
The heterogeneous distribution of hypertrophy in
HCM results in a distortion of internal LV shape allow-
ing algorithms, generally used to measure LV mass, not
applicable in this disease. As a consequence, several
echocardiographic indexes have been developed to mea-
sure the distribution and the extent of LV hypertrophy.
Wigle et al [18] proposed a points score system which
takes into account the degree of septal thickness, start-
ing from a value of 15 mm, and the extension of
Figure 1 Systolic anterior motion (SAM) of the mitral valve visualized by M-Mode echocardiography. X represent the duration of SAM,
whereas Y represent the time elapsed between the beginning of SAM and the SAM-septal contact (see text for more details).
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hypertrophy up to the point of the apex. In order to cal-
culate this score, the apical 4- chamber view is used to
determine the extent of septal involvement, and the
parasternal short-axis view at level of the mitral valve
leaflet tips to determine the anterolateral wall involve-
ment (Figure 5). Also, Spirito et al [15] have developed
a system for assessing the magnitude of hypertrophy
using the parasternal long and short-axis views and api-
cal views (Figure 5). The overall extent of hypertrophy is
defined as mild if only one LV segment is involved,
moderate if two segments are involved and severe if
three or more segments are involved [15] (Figure 5).
Moreover, an index of hypertrophy, the Spirito-Maron
index, is obtained by adding the maximal wall thickness
of each LV segments. The most clinical important
method is the measurement of the maximal wall thick-
ness (MWT) at any LV level [19] (Figure 5). Extreme
wall thickness, i.e. ≥ 30 mm, which can be detected at
any site of LV wall, is observed less commonly in older
than in younger patients, probably because of sudden
death (SD) at a young age and/or of structural remodel-
ing with wall thinning increasing with age. Spirito et al
[20] showed that a maximum thickness of 30 mm or
more, present in approximately 10% of HCM patients,
resulted in a substantial long-term risk. However, Elliot
et al [21] suggested that extreme hypertrophy is a pre-
dictor of SD only when associated with other risk fac-
tors such as unexplained syncope, family history of
premature SCDs, non-sustained ventricular tachycardia
at at Holter-ECG, or an abnormal blood pressure
response during exercise. Furthermore, Olivotto et al
[22] in a community-based population with HCM
reported, during 12-year follow-up, association between
maximum LV thickness and SD only in patients diag-
nosed at a very young age.
The degree of LV hypertrophy varies throughout life.
In fact, although the gross phenotypic expression and
clinical profile of HCM may occasionally be identified in
infants and young children, marked LV hypertrophy is
rarely documented during the first years of life [23].
Conversely, rapid changes in LV morphology often
occur during adolescence and are frequently delayed
completely until the second decade of life, when LV
wall thickness may increase rapidly.
Genetic studies among large families demonstrated
that morphological LV hypertrophy reaches a plateau at
the third decade of life in b-myosin heavy chain and in
a-tropomyosin mutations, whereas it increases continu-
ously thought life in cardiac myosin binding protein C
mutations [24]. The clinical implication of such an
observation is that, in the contest of family screening,
repeat echocardiogram to identify LV hypertrophy at
yearly intervals is reasonable during adolescence,
whereas repeat imaging is considered for adults at
longer time intervals of 5 years. All myocardial seg-
ments, and not only the interventricular septum, should
be carefully examined for screening purposes. In a
recent study where genotyping was the gold standard,
Figure 2 Left ventricular walls dived in four regions in a patients with HCM. Right panel. Apical view in a patient with apical hypertrophy.
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Figure 3 Examples of patients with hypertrophic cardiomyopathy with typical asymmetrical left ventricular hypertrophy.
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the Spirito-Maron hypertrophy score was highly specific
with a better sensitivity than MWT [25].
Although LV remodeling in children is characterized
by progression of hypertrophy, the changes in cardiac
morphology observed in some adults with HCM occur
in the context of development of systolic dysfunction
(defined as LV ejection fraction <50%) associated or not
to LV wall thinning [26] (Figure 6). This unfavorable
evolution in the natural history of HCM usually devel-
ops during midlife in about 4% of patients [27]. This
phase defined end stage (ES) HCM is a cause of pro-
gressive heart failure and is characterized by substantial
cardiac remodeling and gradual evolution from the typi-
cal hypertrophied, non-dilated, and hyper-dynamic state
to one of systolic dysfunction. ES diagnosis is primarily
dependent on ejection fraction <50%, and ES commonly
does not present as a dilated cardiomyopathy, with only
almost 50% of patients showing associated LV cavity
enlargement or regression in wall thickness; a small pro-
portion of ES patients even demonstrate persistent
marked hypertrophy with non-dilated left ventricle [27].
Clinical course is variable but generally unfavorable, and
vigilant follow-up are required for timely identification
of transition to ES, in order to establish appropriate
pharmacological treatment for systolic pump failure,
implantable defibrillator for sudden death prevention,
heart transplantation.
Cross-sectional echocardiographic analyses of large
HCM patient populations encompassing a broad age
spectrum [28,29] have documented morphologic differ-
ences between youthful and older patients indicating that
gradual LV remodeling involving some degree of wall
thinning may occur slowly over decades and may be an
obligatory pathway in the natural history of HCM [28]
At opposite site, there is evidence of high degree of
hypertrophy suggestive of HCM in elderly patients with
and without history of arterial hypertension [30,31]. In
these patients genetic and family screening are recom-
mended, although technique such as Tissue Doppler
Imaging (TDI) and/or strain rate imaging may help in
the differential diagnosis as reported below [32].
Finally, among the spectrum of sarcomeric contractile
protein disease, idiopathic restrictive cardiomyopathy is
part of the clinical expression of cardiac troponin I
mutations [33].
LV hypertrophy in other forms of genetic diseases
Echocardiography can visualize thickened LV walls
with high sensibility and specificity, however it cannot
distinguish conditions based on myocyte hypertrophy
from those in which LV mass and wall thickness are
increased by interstitial infiltration or intracellular
accumulation of metabolic substrates. Cardiac mag-
netic resonance (MRI) may help into diagnostic iter
Figure 4 Patient with left ventricular non compaction. This patient was sottoposed to echocardiography in the contest of family screening
for apical hypertrophic cardiomyopathy.
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(see below), moreover the final diagnosis is given only
in some specific conditions by myocardial biopsy, and
in particular is not indicated for the final diagnosis of
HCM [34,35]. On the other hands, it is not reasonable
to investigate for each entity capable of induce
increased wall thickness because of anamnestic, clinical
and instrumental data that serve to orient the diagno-
sis before the echocardiographic study.
In the contest of genetic disease, thickening of LV
walls can results also by mutations in non sarcomeric
proteins involving or the gene encoding the g-2-regula-
tory subunit of the AMP-activated protein kinase
(PRKAG2), or the gene encoding lysosome-associated
membrane protein 2 (LAMP-2), resulting in Danon-type
storage disease with clinical manifestations limited lar-
gely to the heart (usually with massive degrees of LV
hypertrophy and ventricular pre-excitation) [9] (Figure 7).
Overall these condition are X-linked, and, thus, important
clinical clues are male gender and young age.
Anderson-Fabry disease is a relatively frequent cause of
idiopathic LV hypertrophy. It is a X-linked lysosomal
storage disorder caused by a-galactosidase mutations and
it is characterized clinically by widespread variety of signs
and symptoms. Cardiac findings include LV hypertrophy,
showing a symmetrical pattern in the majority of cases,
mild diastolic dysfunction and preserved LV ejection frac-
tion as well as no LV outflow tract obstruction (LVOTG)
(Figure 8). The use of a binary appearance at echocardio-
graphy of LV endocardial border has been questioned in
that is not a sensitive marker and it can not be routinely
used to differentiate Anderson-Fabry disease from HCM
[7,8]. Symptomatic cardiac involvement usually occurs in
most affected males, whereas female carriers present with
minimal or no symptoms. Retrospective studies found a
prevalence of Anderson-Fabry disease in 4-6% of patients
previously classified as HCM, suggesting that the disease
should be suspected in male patients with concentric LV
hypertrophy and no family history of HCM or with inheri-
tance consistent with X-linked disease [36].
Mitochondrial disorders result from abnormalities in
mitochondrial DNA and function; mitochondrial DNA
is inherited maternally, and most of these disorders are
Figure 5 Echocardiographic methods to identify the degree and the extension of left ventricular hypertrophy in patients with
hypertrophic cardiomyopathy. LV = left ventricular
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transmitted from mother to children of both sexes. In
some mitochondrial disorders, LV concentric hypertro-
phy is present as well dilated cardiomyopathy, which
probably represents a progression from the hypertrophic
form. In most patients, conduction abnormalities are
present [37] (Figure 9).
Involvement of the heart is a common finding and is
the most frequent cause of death in amyloidosis; cardiac
amyloidosis occurs more commonly in men than in
women, and it is rare before the age of 40 years. The
onset of clinical cardiac disease usually occurs late in
life. Echocardiography is characterized in the majority of
cases by symmetric LV hypertrophy, dilated atria and
pericardial effusion (Figure 10). In some case the degree
and the distribution of hypertrophy may resemble
HCM, however LV hypertrophy together with the
Figure 6 Patient with end stage hypertrophic cardiomyopathy: note the absence of thinning: the left ventricular ejection fraction is
40%.
Figure 7 Patient with extreme left ventricular symmetrical hypertrophy. At electrocardiography patient showed a short PR. The patient was
referred for aminotransferase and creatinine phosphokinase dosage and for genetic testing.
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evidence of low voltage at electrocardiogram help in the
differential diagnosis with pericardial effusion and with
HCM [38].
Athletic heart and HCM
One of the most discussed issue is how to role out HCM
in athletes. Diagnosis of HCM in athletes is important,
given the high propensity to sudden cardiac death in
HCM patients engaging in competitive sports as well as
other physically intense activity [39]. Although in Italy
the ECG, which is routinely performed in competitive
athletes, has dramatically reduced the incidence of sud-
den death due to the identification of diseases such as
HCM [40], sometimes the diagnosis can be still particu-
larly challenging in athletes with an advanced degree of
physiologic LV hypertrophy. Cardiac hypertrophic
Figure 8 Young male with definitive diagnosis of Anderson- Fabry disease. For courtesy of Dr L. Spinelli.
Figure 9 Patient with definite diagnosis of mithocondropathy done by neurologists. Echocardiography shows mild symmetric hypertrophy
with mild reduction of left ventricular ejection fraction. During follow-up patient developed severe grade of AV block needing pace-maker and
severe reduction of ejection fraction needing resynchronization.
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response to training is different between sports [41],
between individuals of the same race undergoing the
same training [42], and is different between races [43];
thus, there is a very huge variability in LV hypertrophy in
athletes, which sometimes is suggestive of HCM. Helpful
clues include the presence of wall thickness >12 mm in
the presence of a non-dilated LV in HCM, because HCM
patients usually have normal or reduced LV dimensions
and no cavity dilatation (>55 mm is common in athletes),
except with disease progression and systolic dysfunction.
HCM patients have abnormal myocardial function as
detected by TDI, including mitral annulus velocities or
strain rate [44]. In equivocal cases, it is reasonable to
recommend stopping exercise with repeat imaging later,
when one would expect regression of physiologic but not
pathologic LV hypertrophy [44,45].
In Figure 11 we suggest a clinical and echocardio-
graphic method to approach patients with unexplained
LV hypertrophy.
Right ventricular hypertrophy
Right ventricular hypertrophy is diagnosed when two or
more right ventricular segments are hypertrophied and
when at least two right ventricular wall measurements
exceed two standard deviations from the mean recorded
in normal subjects. Using these criterions McKenna
et al [46] reported right ventricular hypertrophy in 44%
of 73 patients with HCM. More recently, Maron at al
found [47] in 46 HCM patients studied by cardiac MRI,
that right ventricular mass was increased in the majority
of them. To date, the clinical and prognostic significance
of right ventricular hypertrophy is not known.
LVOTG
Although SAM is the most frequent mechanism of
LVOTG, obstruction can occur at mid-ventricular level
or at multiple levels in the same patient and is variable
with time. Continuous Doppler will give informations
about the degree of obstruction (see later) whereas by
pulse wave Doppler LV mapping will be performed to
determine the site of obstruction. Mid-ventricular
obstruction has been diagnosed by the typical angio-
graphic feature of hourglass appearance of the left ventri-
cle with mid-ventricular obliteration and apical chamber
that is variable in size and contractility. Echocardiography
has the same potential to identify this haemodynamic
type of HCM (Figure 12). Patients with mid-ventricular
obstruction are at high risk to develop segmental, like
apical aneurysm, or diffuse LV wall motion abnormalities
[48]. Moreover, structural abnormalities of the mitral
valve, such as increased mitral valve area and abnormal
direct insertion of papillary muscles into anterior mitral
leaflet (Figure 13) can be detected by echocardiography
orienting treatments’ strategies.
LA volume
LA volume measured by two-dimensional echocardio-
graphy has some clinical and prognostic implications.
Figure 10 Patient with definitive diagnosis of amyloidosis. Note the pericardial effusion.
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LA remodeling, measured by LA volume, relates directly
with exercise tolerance as demonstrated by Sachdev
et al [49] in patients without LVOTG either at rest and
during provocation, suggesting that this parameter may
serve as a surrogate marker of chronic diastolic burden.
Moreover, patients with normal LA volume which show
dilatation during follow-up, i.e. >3 ml/year, have a worse
outcome than patients with normal and stable LA
volume during follow-up and similar to that of patients
with LA dilation at baseline [50].
Doppler echocardiography
Each Doppler technique offers relevant contribution in
the analysis of patients with HCM .
Color Doppler echocardiography
Evaluation of the presence and degree of mitral regurgita-
tion is performed by color Doppler echocardiography.
Mitral regurgitation occurs in almost all patients with
obstructive HCM as a consequence of SAM which induces
abnormal mitral leaflet coaptation and may be an impor-
tant cause of dyspnea. When additional mitral valve
abnormalities other than SAM are not observed, a direct
relation between the pressure gradient and the severity of
MR is evident [51]. The direction of the mitral regurgita-
tion jet is useful in identifying patients with independent
mitral disease. In fact SAM induces a mitral regurgitation
jet directed posteriorly, whereas in presence of a intrinsic
mitral valve disease due to annular, papillary or leaflet dis-
ease, patients with obstruction and mitral regurgitation
can show a systolic mitral anterior directed jet [51].
Continuous Doppler echocardiography. Exercise
echocardiography
Approximately 25% of patients with HCM have a signifi-
cant resting pressure gradient, i.e. ≥30 mmHg, between
the body and LV outflow tract. This is nearly always
accompanied by SAM. Continuous wave Doppler is
used to determine peak LVOTG with caution exercised
to exclude the mitral regurgitation jet [52] (Figure 14).
This latter differentiation may be difficult especially in
patients with mitral regurgitation jet directed anteriorly.
In these cases it is of help the M-mode echocardio-
graphic evaluation of SAM.
It is well recognized that some patients without out-
flow obstruction at rest have gradients that can be pro-
voked by physiological and pharmacological
interventions that diminish LV end-diastolic volume or
augment LV contractility. The term labile obstruction
has been used to describe the spontaneous appearance
and disappearance of obstruction and latent obstruction
Figure 11 Scheme for the clinical and echocardiographic approach in patients with unexplained left ventricular hypertrophy. LV = left
ventricular
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to describe gradients that only appear with provocation.
A number of methods can provoke obstruction in the
echocardiography laboratory, including Valsalva maneu-
ver, amyl nitrite, and dobutamine. However, these meth-
ods are not standardized and can underestimate the
degree of obstruction such as Valsalva maneuver or
have low specificity such as dobutamine. Exercise is a
physiologic means of provoking latent LVOTG. Over
50% of HCM patients without significant outflow tract
obstruction at rest will demonstrate outflow gradients
over 30 mmHg with exercise [53,54]. Although supine
bike exercise is more conducive to acquiring multiple
haemodynamic data sets, this position increases venous
return and might decrease the likelihood and extent of
LVOTG. Accordingly, upright exercise, which has the
greatest resemblance to daily physiologic activities,
should be used.
Right ventricular outflow tract obstruction may coexist
with LVOTG in a minority of patients with massive sep-
tal hypertrophy and occasionally it is isolated [55].
Figure 15 shows the echo findings which are strong
predictors of prognosis in patients with HCM.
Pulsed Doppler
Pulsed Doppler at mitral and pulmonary level is used to
assess the presence and the degree of diastolic dysfunc-
tion. Almost all patients with HCM have some degree of
LV diastolic dysfunction. Figure 16 reports a scheme of
the molecular, morphological and haemodynamic factors
which may contribute to diastolic dysfunction in HCM.
These complex mechanisms determine that all phases of
diastole are altered. Isovolumic relaxation is slowed and
prolonged, the rate of rapid filling is diminished, atrial
contribution to filling is increased as well as LV chamber
stiffness [56]. The importance of diastolic dysfunction in
HCM has led to an extensive search for accurate, nonin-
vasive methods of quantifying its severity. When LV end-
diastolic pressure is considered, the echo pulsed Doppler
parameter with a good relationship is represented by the
difference in duration between the atrial contraction
wave at mitral and pulmonary level [57]. Lombardi et al
[58] demonstrated that as the difference in duration wor-
sens myocardial collagen synthesis prevails over degrada-
tion; moreover, an echocardiography index of myocardial
fibrosis, i.e. diastolic back scatter, increases [59], suggest-
ing a strong interplay between diastolic function and
myocardial fibrosis.
New echocardiographic technologies
New technologies have been employed in the patho-
physiological assessment, in preclinical diagnosis, in dif-
ferential diagnosis, and in risk stratification of HCM.
Contrast echocardiography
Contrast echocardiography currently is used to enhance
endocardial definition, Doppler signals, and to evaluate
myocardial perfusion during percutaneous transluminal
septal myocardial ablation (PTSMA). PTSMA is a cathe-
ter interventional treatment which involves the intro-
duction of absolute alcohol into a septal perforator
branch of the left anterior descending coronary artery to
produce a myocardial infarction within the proximal
ventricular septum. The aim is similar to that of myot-
omy-myectomy, i.e. reducing the basal septal thickness
and excursion enlarging the LV outflow tract and,
thereby, lessening the SAM of the mitral valve and
Figure 12 Mid ventricular obstruction with an hourglass
appearance.
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Figure 13 Example of patients with abnormal direct insertion of papillary muscles into anterior mitral leaflet.
Figure 14 Differentiation between mitral regurgitation (first cardiac cycles) and left ventricular outflow tract gradient (last cardiac
cycles). This was obtained by orienting the probe more medially and anteriorly.
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mitral regurgitation. The introduction of the echo con-
trast has proved to reduced the side effects of the tech-
nique: it selects the appropriate septal perforator branch
determining the precise area of septum targeted for
alcohol ablation and evaluates whether selected septal
perforator also perfuses other distant and unwanted
areas of LV or right ventricular myocardium or papillary
muscles [60].
A potential role for contrast enhancement in the diag-
nosis of apical HCM has been demonstrated [61],
although systematic studies have not be yet performed.
Tissue Doppler Imaging
Given the complex interplay of factors causing diasto-
lic dysfunction in HCM, it should not be surprising
that no single non-invasive measure has been defini-
tively validated. Nagueh et al [57] suggested that the
ratio of early transmitral (E) to tissue Doppler early
diastolic (e’) velocities of the lateral mitral annulus
accurately quantified LV pressures, in particular the
LV pressure before atrial contraction, an E/e’ ≥10
showed the best sensitivity and specificity for identify-
ing LV pre-A pressure > 15 mmHg. However, that
ratio shows only a modest correlation when related to
mean left atrial (LA) pressure, and, moreover, the pre-
dictive accuracy of the E/e’ ratio for estimation of
mean LA pressure in an individual patient was modest
[62]. However, in some study this parameter identifies
patients with low exercise capacity [63,64].
Figure 15 Echocardiographic findings and their prognostic impact in patients with HCM.
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TDI has been investigated in the preclinical diagnosis
of HCM. Studies from transgenic animal models
revealed some abnormal myocardial function at a time
preceding the development of LV hypertrophy, firstly
due to alterations in Ca++ sensitivity [65] which prob-
ably induce low TDI velocities at annular mitral level.
Although some reports have provided encouraging
results [66,67], additional data from a larger number of
subjects are needed to determine TDI velocity values
that provide the highest diagnostic accuracy.
Strain rate imaging
Patients with HCM may show regional differences in
wall motion at rest [45]. Betocchi et al [68] demon-
strated that LV regions with less pronounced myopathic
process are those with normal stiffness and with super-
normal wall motion. In contrast, the stiffer septum
Figure 16 Mechanisms linked to diastolic dysfunction in patients with hypertrophic cardiomyopathy. Dashed lines represent links not yet
well demonstrated.
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shows reduced wall motion compared with adjacent
regions. Other mechanisms may explain regional asy-
nergy such as anatomic nonuniformity, altered calcium
handling, subendocardial ischemia and altered glucose
metabolism.
In the last decade several papers have been published
using strain rate technique, either TDI and speckle (2D
gray-scale method), to investigate regional systolic func-
tion. Ganame et al [69] demonstrated in a pediatric
population with HCM that, despite normal global systolic
function, longitudinal and radial systolic myocardial
deformation were heterogeneously reduced and the
alteration was more pronounced in the more severely
hypertrophied myocardial segments. There are discre-
pancies between measures of regional and global myocar-
dial functions for several reasons. Endocardial indexes of
LV function such as fractional shortening and ejection
fraction are known to overestimate systolic function in
the presence of LV hypertrophy. Moreover, patients with
HCM have a smaller end-diastolic diameter and
increased wall thickness, resulting in a decreased ventri-
cular afterload which, in presence of significant hypertro-
phy, will result in higher values of fractional shortening
and ejection fraction, despite reduced wall thickening.
When regional systolic function was studied by strain
rate imaging, there was a direct relationship between sys-
tolic deformation and exercise capacity in a pediatric
population with HCM, suggesting that systolic function,
even when ejection fraction is normal or supernormal,
has a role into determination of clinical status in these
selected group of patients. In another study, a regional
double peak systolic sign indicating a second systolic
peak during systole, had strong relationship with the late
enhancement at nuclear magnetic resonance, suggesting
the possibility to diagnose regional myocardial fibrosis by
echocardiography [70] (Figure 17).
Strain rate imaging has been shown to measure accu-
rately LV torsion [71]. LV untwisting is linked tempo-
rally with early diastolic base-to-apex pressure gradients,
enhanced by exercise, which may assist efficient LV fill-
ing. This effect appears blunted during exercise in HCM
[72], particularly in patients with the obstructive form
[73].
A frequent clinical issue is to establish the final diag-
nosis in patients with high degree of LV hypertrophy
and arterial hypertension; recently, more severely
reduced systolic compression (by strain Doppler echo-
cardiography) along with asymmetric LV hypertrophy
readily identified HCM patients from those with hyper-
tension [32]. Receiver-operator characteristic curve ana-
lysis identified the optimal cut-off value of strain, i.e.
systolic longitudinal strain by 4 and 2 chamber views,
for discrimination between HCM and hypertensive LV
hypertrophy, as -10.6%; this value was associated with a
sensitivity, specificity, and predictive accuracy of 85, 100,
and 91.2%, respectively. Similarly, an intraventricular
septal/posterior wall thicknesses ratio of 1.3 was asso-
ciated with a sensitivity of 65%, specificity of 100%, and
predictive accuracy of 79.4%. A discriminant function
test revealed that a discriminant score (Z) defined by
the following equation yielded the highest discriminant
probability of 96.1%: Z = -1.7044 + (15.2316 × IVST/
PWT) + (1.52687 × strain), where Z > 0 indicates a
diagnosis of HCM and Z < 0 indicates a diagnosis of
hypertensive LV hypertrophy.
Strain rate imaging has been involved in the differen-
tiation of HCM from cardiac amyloidosis in one study
where, however, patients with amyloidosis were in the
late stage characterized by low ejection fraction. This
suggests that the early differentiation of amyloidosis ver-
sus HCM using strain (i.e., before the development of
systolic dysfunction) may be still difficult [74].
Real time 3-dimensional echocardiography
Real time 3-dimensional echocardiography has been
applied to determine LV mass, but there is a paucity of
data about its accuracy in HCM. To date, MWT
remains the best and the more simple and important
measurement that should be reported, because it can
predict sudden cardiac death in this population.
Coronary flow reserve
Stress echocardiography with dypiridamole has been
used to test prognostic role of electrographic signs of
inducible ischemia in patients with HCM. In one paper
[75], ECG signs of myocardial ischemia elicited by
dipyridamole were frequent identify patients at higher
risk of cardiac major and minor events, suggesting a
important pathogenetic role of inducible myocardial
ischemia in determining adverse cardiac events in these
patients.
Quantitative evaluation of coronary flow reserve stu-
died by positron emission tomography is a strong pre-
dictor of progression to severe symptoms and to ES
HCM [76]. An estimate of coronary flow reserve can be
obtained in the echo-lab by the simple transthoracic
Doppler echocardiographic approach of the mid-distal
left anterior descending artery and recently its prognos-
tic role has been tested in a population of patients with
HCM. Cortigiani et al [77], found that patients with
reduced coronary flow reserve (≤2) have a worse prog-
nosis than patients with normal values (>2). Clinical
events recorded during follow-up were death, nonfatal
myocardial infarction (defined by typical symptoms,
increased cardiac enzyme, and/or electrocardiographic
changes), cardioverter- defibrillator implantation, hospi-
talization for heart failure or unstable angina, syncope,
and paroxysmal or chronic atrial fibrillation. Authors
found that this coronary flow reserve was a strong and
independent predictor of outcome in HCM patients.
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MRI
MRI is an important imaging technique with an expand-
ing role in the contemporary evaluation of patients with
HCM; it provides complete LV reconstruction and a
precise definition of the distribution and pattern of
hypertrophy [78]. This is particularly useful in patients
without a clear LV anatomic characterization by echo-
cardiography. Measurements of MWT by echocardiogra-
phy and by MRI are strictly related whereas MWT
shows weak relationship when related to LV mass
[79,80].
In patients highly suspected to have HCM, but with a
negative echocardiogram for LV hypertrophy, MRI
represents an additive diagnostic chance as proposed by
Rickers et al; Authors found, in a population involving
almost 50 patients, that MRI was capable of identifying
regions of LV hypertrophy (in particular at anterolateral
level) not readily recognized by echocardiography, which
were solely responsible for diagnosis of the HCM phe-
notype in an important minority of patients [81]. More-
over, the measure of LV mass and the characterization
of abnormal substrate of fibrosis will probably provide
implications of these findings in the risk stratification
[81]. Nevertheless, it must be underscored that MRI
doesn’t provide complete LV tissue characterization and,
thus, can not be used as a non-invasive biopsy.
Genetic testing
The diagnosis of HCM is most easily and reliably estab-
lished by clinical and instrumental examination in the
majority of affected adult patients. Thus, in patients
with certain clinical diagnosis, genetic testing represents
only a diagnostic confirmation. Nevertheless, molecular
studies have the potential to enhance diagnostic reliabil-
ity in HCM and can play an important role in resolving
ambiguous diagnoses [82]. Moreover, in selected pedi-
grees genetic testing, has led to the identification of
increasing numbers of children and adults with a precli-
nical diagnosis of HCM. These individuals have a dis-
ease-causing genetic mutation but no clinical or
phenotypic manifestations of HCM. At present, there is
no available evidence to justify precluding such
Figure 17 Example of post-systolic strain in a patient with HCM.
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genotype-positive, phenotype-negative individuals from
most employment opportunities or life activities; how-
ever, a family history of frequent HCM-related death or
the documentation of a particularly malignant genotype
may justify efforts at risk stratification and possible
restriction from competitive sports. Such a clinical sce-
nario suggest that it is extremely important that family
members receive careful counseling both before and
after testing [83].
Conclusion
Two-dimensional echocardiography has been the most
used, efficient and accessible technique for establish-
ment of the diagnosis of HCM. Echocardiography can
provide important information for the appropriate diag-
nosis and pathophysiological assessment of HCM
patients. However, echocardiography alone can not dif-
ferentiate different forms of unexplained LV hypertro-
phy. It must be underscore that its role is highlight only
when is used after a complex clinical evaluation includ-
ing familial and personal anamnesis, clinical examina-
tion, electrocardiogram, haemato-chemical tests.
Author details
1Department of Clinical Medicine, Cardiovascular and Immunological
Sciences, University Federico II, Naples, Italy. 2CMSR Veneto Medica -Altavilla
Vicentina, Italy. 3Department of Clinical and Experimental Medicine,
University Federico II, Naples, Italy. 4Referral Center for Myocardial Diseases,
Careggi University Hospital, Florence. 5Noninvasive Cardiology Unit, Ospedale
San Raffaele, IRCCS, Milano, Italy. 6Cardiology Operative Unit, S. Maria
Annunziata Hospital, Firenze, Italy. 7Department of Clinical Medicine,
University of Pisa, Pisa, Italy. 8Chair of Cardiology, Second University of
Naples, Naples, Italy. 9Azienda Ospedaliera Universitaria, Ferrara, Italy.
10Department of Cardiovascular, Respiratory and Morphological Sciences,
University of Rome, University La Sapienza, Rome, Italy. 11Department of
Cardiovascular Diseases, University of Siena, Italy.
Authors’ contributions
MAL conceived the review and drafted the manuscript. SN e MG suggested
the scheme of the review and revised critically the paper. SB revised
critically the manuscript and added figures which resulted in a more
readable manuscript. FC and IO revised critically the manuscript and gave
important changes before the final submission. EA and PB performed a
statistical analysis when necessary and revised critically part of the
bibliography giving important criticism on the prognostic role of echo in
patients with HCM. SB and ADA helped in the collection of the bibliography
suggesting some important papers reported in the review and improved
the chapters concerning the differential diagnosis in patients with HCM. ADE
and DM contributed and improved the chapters concerning the role of new
technologies. SS participated in the design of the review. SM participated in
the design of the review and gave the final approval. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 27 January 2010 Accepted: 17 March 2010
Published: 17 March 2010
References
1. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ,
Seidman CE, Shah PM, Spencer WH, Spirito P, Ten Cate FJ, Wigle ED: ACC/
ESC clinical expert consensus document on hypertrophic
cardiomyopathy: a report of the American College of Cardiology Task
Force on Clinical Expert Consensus Documents and the European
Society of Cardiology Committee for Practice Guidelines (Committee to
Develop an Expert Consensus Document on Hypertrophic
Cardiomyopathy). J Am Coll Cardiol 2003, 42:1687-713.
2. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D,
Moss AJ, Seidman CE, Young JB: Contemporary definitions and
classification of the cardiomyopathies. Circulation 2006, 113:1807-16.
3. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P,
Dubourg O, Kühl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S,
Rapezzi C, Seferovic P, Tavazzi L, Keren A: Classification of the
cardiomyopathies: a position statement from the European Society Of
Cardiology Working Group on Myocardial and Pericardial Diseases. Eur
Heart J 2008, 29:270-6.
4. Doi YL, McKenna WJ, Oakley CM, Goodwin JF: ’Pseudo’ systolic anterior
motion in patients with hypertensive heart disease. Eur Heart J 1983,
4:838-45.
5. Pollick C, Rakowski H, Wigle ED: Muscular subaortic stenosis: the
quantitative relationship between systolic anterior motion and the
pressure gradient. Circulation 1984, 69:43-9.
6. Maron BJ, Edwards JE, Epstein SE: Prevalence and characteristics of
disproportionate ventricular septal thicknening in patients with systemic
hypertension. Chest 1978, 73:466-70.
7. Pieroni M, Chimenti C, De Cobelli F, Morgante E, Del Maschio A, Gaudio C,
Russo MA, Frustaci A: Fabry’s disease cardiomyopathy: echocardiographic
detection of endomyocardial glycosphingolipid compartmentalization. J
Am Coll Cardiol 2006, 47:1663-71.
8. Kounas S, Demetrescu C, Pantazis AA, Keren A, Lee PJ, Hughes D, Mehta A,
Elliott PM: The binary endocardial appearance is a poor discriminator of
Anderson-Fabry disease from familial hypertrophic cardiomyopathy. J
Am Coll Cardiol 2008, 51:2058-61.
9. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR,
Spirito P, Wright GB, Kanter RJ, Seidman CE, Seidman JG: Glycogen storage
diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005,
352:362-72.
10. Gottdiener JS, Hawley RJ, Maron BJ, Bertorini TF, Engle WK: Characteristics
of the cardiac hypertrophy in Friedreich’s ataxia. Am Heart J 1982,
103:525-31.
11. Nistri S, Olivotto I, Betocchi S, Losi MA, Valsecchi G, Pinamonti B, Conte MR,
Casazza F, Galderisi M, Maron BJ, Cecchi F: Prognostic significance of left
atrial size in patients with hypertrophic cardiomyopathy (from the
Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol 2006,
98:960-5.
12. Briguori C, Betocchi S, Losi MA, Manganelli F, Piscione F, Pace L,
Boccalatte M, Gottilla R, Salvatore M, Chiariello M: Noninvasive evaluation
of left ventricular diastolic function in hypertrophic cardiomyopathy. Am
J Cardiol 1998, 81(2):180-7.
13. Briguori C, Betocchi S, Romano M, Manganelli F, Losi MA, Ciampi Q,
Gottilla R, Lombardi R, Condorelli M, Chiariello M: Exercise capacity in
hypertrophic cardiomyopathy depends on left ventricular diastolic
function. Am J Cardiol 1999, 84:309-15.
14. Losi MA, Betocchi S, Aversa M, Lombardi R, Miranda M, D’Alessandro G,
Cacace A, Tocchetti CG, Barbati G, Chiariello M: Determinants of atrial
fibrillation development in patients with hypertrophic cardiomyopathy.
Am J Cardiol 2004, 94:895-900.
15. Spirito P, Maron BJ, Chiarella F, Bellotti P, Tramarin R, Pozzoli M, Vecchio C:
Diastolic abnormalities in patients with hypertrophic cardiomyopathy:
relation to magnitude of left ventricular hypertrophy. Circulation 1985,
72:310-6.
16. Klues HG, Schiffers A, Maron BJ: Phenotypic spectrum and patterns of left
ventricular hypertrophy in hypertrophic cardiomyopathy morphologic
observations and significance as assessed by two-dimensional
echocardiography in 600 patients. J Am Coll Cardiol 1995, 26:1699-708.
17. Monserrat L, Hermida-Prieto M, Fernandez X, Rodríguez I, Dumont C,
Cazón L, Cuesta MG, Gonzalez-Juanatey C, Peteiro J, Alvarez N, Penas-
Lado M, Castro-Beiras A: Mutation in the alpha-cardiac actin gene
associated with apical hypertrophic cardiomyopathy, left ventricular
non-compaction, and septal defects. Eur Heart J 2007, 28:1953-61.
18. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H,
Williams WG: Hypertrophic cardiomyopathy. The importance of the site
Losi et al. Cardiovascular Ultrasound 2010, 8:7
http://www.cardiovascularultrasound.com/content/8/1/7
Page 17 of 19
and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985,
28:1-83.
19. Spirito P, Maron BJ: Relation between extent of left ventricular
hypertrophy and occurrence of sudden cardiac death in hypertrophic
cardiomyopathy. J Am Coll Cardiol 1990, 15:1521-6.
20. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ: Magnitude of
left ventricular hypertrophy and risk of sudden death in hypertrophic
cardiomyopathy. N Engl J Med 2000, 342:1778-85.
21. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ:
Relation between severity of left-ventricular hypertrophy and prognosis
in patients with hypertrophic cardiomyopathy. Lancet 2001, 357:420-4.
22. Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, Cecchi F: Maximum
left ventricular thickness and risk of sudden death in patients with
hypertrophic cardiomyopathy. J Am Coll Cardiol 2003, 41:315-21.
23. Maron J, Spirito P: Implications of left ventricular remodeling in
hypertrophic cardiomyopathy. Am J Cardiol 1998, 81:1339-44.
24. Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE,
McKenna W, Kristinsson A, Roberts R, Sole M, Maron BJ, Seidman JG,
Seidman CE: Mutations in the gene for cardiac myosin-binding protein C
and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998,
338:1248-57.
25. Forissier JF, Charron P, Tezenas du Montcel S, Hagège A, Isnard R, Carrier L,
Richard P, Desnos M, Bouhour JB, Schwartz K, Komajda M, Dubourg O:
Diagnostic accuracy of a 2D left ventricle hypertrophy score for familial
hypertrophic cardiomyopathy. Eur Heart J 2005, 26:1882-6.
26. Biagini E, Coccolo F, Ferlito M, Perugini E, Rocchi G, Bacchi-Reggiani L,
Lofiego C, Boriani G, Prandstraller D, Picchio FM, Branzi A, Rapezzi C:
Dilated-hypokinetic evolution of hypertrophic cardiomyopathy:
prevalence, incidence, risk factors, and prognostic implications in
paediatric and adult patients. J Am Coll Cardiol 2005, 46:1543-50.
27. Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR,
Mackey-Bojack S, Manning WJ, Udelson JE, Maron BJ: Prevalence, clinical
profile, and significance of left ventricular remodeling in the end-stage
phase of hypertrophic cardiomyopathy. Circulation 2006, 114:216-25.
28. Spirito P, Maron BJ: Relation between extent of left ventricular
hypertrophy and age in patients with hypertrophic cardiomyopathy. J
Am Coll Cardiol 1989, 13:820-823.
29. Maron BJ, Casey SA, Hurrell DG, Aeppli DM: Relation of left ventricular
thickness to age and gender in hypertrophic cardiomyopathy. Am J
Cardiol 2003, 91:1195-98.
30. Topol EJ, Traill TA, Fortuin NC: Hypertensive hypertrophic cardiomyopathy
in the elderly. N Eng J Med 1985, 312:277-83.
31. Niimura H, Patton KK, McKenna WJ, Soults J, Maron BJ, Seidman JG,
Seidman CE: Sarcomere protein gene mutations in hypertrophic
cardiomyopathy of the elderly. Circulation 2002, 105:446-51.
32. Kato TS, Noda A, Izawa H, Yamada A, Obata K, Nagata K, Iwase M,
Murohara T, Yokota M, et al: Discrimination of nonobstructive
hypertrophic cardiomyopathy from hypertensive left ventricular
hypertrophy on the basis of strain rate imaging by tissue Doppler
ultrasonography. Circulation 2004, 110:3808-14.
33. Kubo T, Gimeno JR, Bahl A, Steffensen U, Steffensen M, Osman E,
Thaman R, Mogensen J, Elliott PM, Doi Y, McKenna WJ: Prevalence, clinical
significance, and genetic basis of hypertrophic cardiomyopathy with
restrictive phenotype. J Am Coll Cardiol 2007, 49:2419-26.
34. Leone O, Rapezzi C, Sinagra G, Angelini A, Arbustini E, Bartoloni G, Basso C,
Caforio ALP, Calabrese F, Coccolo F, d’Amati G, Maresi E, Milanesi O,
Nodali S, Oliva F, Perkan A, Prandstraller D, Pucci A, Ramando A, Silvestri F,
Valente M, Thiene G: Documento di consenso sulla biopsia
endomiocardica promosso dall’Associazione per la Patologia
Cardiovascolare Italiana. G Ital Cardiol 2009, 10(Suppl 1-9):18S-50S.
35. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U,
Levine GN, Narula J, Starling RC, Towbin J, Virmani R, American Heart
Association; American College of Cardiology; European Society of
Cardiology: The role of endomyocardial biopsy in the management of
cardiovascular disease: a scientific statement from the American Heart
Association, the American College of Cardiology, and the European
Society of Cardiology. Circulation 2007, 116:2216-33.
36. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, Elliott PM:
Prevalence of Anderson-Fabry disease in male patients with late onset
hypertrophic cardiomyopathy. Circulation 2002, 105:1407-11.
37. Groh WJ, Zipes DP: Neurological disorders and cardiovascular disease.
Heart Disease. A textbook of cardiovascular medicine Philadelphia. Elsevier
SaundersBranwald E , 7 2005.
38. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH: Familial and primary
(AL) cardiac amyloidosis: echocardiographically similar diseases with
distinctly different clinical outcomes. Heart 1997, 78:74-82.
39. Nistri S, Thiene G, Basso C, Corrado D, Vitolo A, Maron BJ: Screening for
hypertrophic cardiomyopathy in a young male military population. Am J
Cardiol 2003, 91:1021-3.
40. Corrado D, Basso C, Schiavon M, Pelliccia A, Thiene G: Pre-participation
screening of young competitive athletes for prevention of sudden
cardiac death. J Am Coll Cardiol 2008, 52:1981-9.
41. Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P: The upper limit of
physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J
Med 1991, 324:295-301.
42. Montgomery HE, Clarkson P, Dollery CM, Prasad K, Losi MA, Hemingway H,
Statters D, Jubb M, Girvain M, Varnava A, World M, Deanfield J, Talmud P,
McEwan JR, McKenna WJ, Humphries S: Association of angiotensin-
converting enzyme gene I/D polymorphism with change in left
ventricular mass in response to physical training. Circulation 1997,
96:741-7.
43. Basavarajaiah S, Boraita A, Whyte G, Wilson M, Carby L, Shah A, Sharma S:
Ethnic differences in left ventricular remodeling in highly-trained
athletes relevance to differentiating physiologic left ventricular
hypertrophy from hypertrophic cardiomyopathy. J Am Coll Cardiol 2008,
51:2256-62.
44. Caso P, D’Andrea A, Caso I, Severino S, Calabrò P, Allocca F, Mininni N,
Calabrò R: The athlete’s heart and hypertrophic cardiomyopathy: two
conditions which may be misdiagnosed and coexistent. Which
parameters should be analyzed to distinguish one disease from the
other? J Cardiovasc Med (Hagerstown) 2006, 7:257-66.
45. Nagueh SF, Mahmarian JJ: Noninvasive cardiac imaging in patients with
hypertrophic cardiomyopathy. J Am Coll Cardiol 2006, 48:2410-22.
46. McKenna WJ, Kleinebenne A, Nihoyannopoulos P, Foale R:
Echocardiographic measurement of right ventricular wall thickness in
hypertrophic cardiomyopathy: relation to clinical and prognostic
features. J Am Coll Cardiol 1988, 1:351-8.
47. Maron MS, Hauser TH, Dubrow E, Horst TA, Kissinger KV, Udelson JE,
Manning WJ: Right ventricular involvement in hypertrophic
cardiomyopathy. Am J Cardiol 2007, 100:1293-8.
48. Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, Lesser JR,
Udelson JE, Ackerman MJ, Maron BJ: Prevalence, clinical significance, and
natural history of left ventricular apical aneurysms in hypertrophic
cardiomyopathy. Circulation 2008, 118:1541-9.
49. Sachdev V, Shizukuda Y, Brenneman CL, Birdsall CW, Waclawiw MA, Arai AE,
Mohiddin SA, Tripodi D, Fananapazir L, Plehn JF: Left atrial volumetric
remodeling is predictive of functional capacity in nonobstructive
hypertrophic cardiomyopathy. Am Heart J 2005, 149(4):730-6.
50. Losi MA, Betocchi S, Aversa M, Lombardi R, Miranda M, Cacace A, Ciampi Q,
Tocchetti CG, Guida A, Chiariello M: Dobutamine stress echocardiography
in hypertrophic cardiomyopathy. Cardiology 2003, 100:93-100.
51. Yu EH, Omran AS, Wigle ED, Williams WG, Siu SC, Rakowski H: Mitral
regurgitation in hypertrophic obstructive cardiomyopathy: relationship
to obstruction and relief with myectomy. J Am Coll Cardiol 2000,
36:2219-25.
52. Panza JA, Petrone RK, Fananapazir L, Maron BJ: Utility of continuous wave
Doppler echocardiography in the noninvasive assessment of left
ventricular outflow tract pressure gradient in patients with hypertrophic
cardiomyopathy. J Am Coll Cardiol 1992, 19(1):91-9.
53. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S,
Cecchi F, Udelson JE, Maron BJ: Hypertrophic cardiomyopathy is
predominantly a disease of left ventricular outflow tract obstruction.
Circulation 2006, 114:2232-9.
54. Shah JS, Esteban MT, Thaman R, Sharma R, Mist B, Pantazis A, Ward D,
Kohli SK, Page SP, Demetrescu C, Sevdalis E, Keren A, Pellerin D,
McKenna WJ, Elliott PM: Prevalence of exercise-induced left ventricular
outflow tract obstruction in symptomatic patients with non-obstructive
hypertrophic cardiomyopathy. Heart 2008, 94:1288-94.
55. Maron BJ, McIntosh CL, Klues HG, Cannon RO, Roberts WC: Morphologic
basis for obstruction to right ventricular outflow in HCM. Am J Cardiol
1993, 71:1089-94.
Losi et al. Cardiovascular Ultrasound 2010, 8:7
http://www.cardiovascularultrasound.com/content/8/1/7
Page 18 of 19
56. Betocchi S, Bonow RO, Bacharach SL, Rosing DR, Maron BJ, Green MV:
Isovolumic relaxation period in hypertrophic cardiomyopathy:
assessment by radionuclide angiography. J Am Coll Cardiol 1986, 7:74-81.
57. Nagueh SF, Lakkis NM, Middleton KJ, Spencer WH, Zoghbi WA,
Quiñones MA: Doppler estimation of left ventricular filling pressures in
patients with hypertrophic cardiomyopathy. Circulation 1999, 99:254-61.
58. Lombardi R, Betocchi S, Losi MA, Tocchetti CG, Aversa M, Miranda M,
D’Alessandro G, Cacace A, Ciampi Q, Chiariello M: Myocardial collagen
turnover in hypertrophic cardiomyopathy. Circulation 2003, 108:1455-60.
59. Losi MA, Betocchi S, Chinali M, Barbati G, D’Alessandro G, Cacace A,
Lombardi R, Contaldi C, de Simone G, Chiariello M: Myocardial texture in
hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2007, 20:1253-9.
60. Nagueh SF, Lakkis NM, He ZX, Middleton KJ, Killip D, Zoghbi WA,
Quinones M, Roberts R, Verani MS, Kleiman NS, Spencer WH III: Role of
myocardial contrast echocardiography during nonsurgical septal
reduction therapy for hypertrophic obstructive cardiomyopathy. J Am
Coll Cardiol 1998, 32:225-9.
61. Soman P, Swinburn J, Callister M, Stephens NG, Senior R: Apical
hypertrophic cardiomyopathy: bedside diagnosis by intravenous
contrast echocardiography. J Am Soc Echocardiogr 2001, 14:311-3.
62. Geske JB, Sorajja P, Nishimura RA, Ommen SR: Evaluation of left ventricular
filling pressures by Doppler echocardiography in patients with
hypertrophic cardiomyopathy: correlation with direct left atrial pressure
measurement at cardiac catheterization. Circulation 2007, 4;116:2702-8.
63. Matsumura Y, Elliott PM, Virdee MS, Sorajja P, Doi Y, McKenna WJ: Left
ventricular diastolic function assessed using Doppler tissue imaging in
patients with hypertrophic cardiomyopathy: relation to symptoms and
exercise capacity. Heart 2002, 87:247-51.
64. McMahon CJ, Nagueh SF, Pignatelli RH, Denfield SW, Dreyer WJ, Price JF,
Clunie S, Bezold LI, Hays AL, Towbin JA, Eidem BW: Characterization of left
ventricular diastolic function by tissue Doppler imaging and clinical
status in children with hypertrophic cardiomyopathy. Circulation 2004,
109:1756-62.
65. Nagueh SF, Chen S, Patel R, Tsybouleva N, Lutucuta S, Kopelen HA,
Zoghbi WA, Quiñones MA, Roberts R, Marian AJ: Evolution of expression
of cardiac phenotypes over a 4-year period in the beta-myosin heavy
chain-Q403 transgenic rabbit model of human hypertrophic
cardiomyopathy. J Mol Cell Cardiol 2004, 36:663-73.
66. Nagueh SF, McFalls J, Meyer D, Hill R, Zoghbi WA, Tam JW, Quiñones MA,
Roberts R, Marian AJ: Tissue Doppler imaging predicts the development
of hypertrophic cardiomyopathy in subjects with subclinical disease.
Circulation 2003, 108(4):395-8.
67. Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG,
Seidman CE, Solomon SD: Assessment of diastolic function with Doppler
tissue imaging to predict genotype in preclinical hypertrophic
cardiomyopathy. Circulation 2002, 105(25):2934-6.
68. Betocchi S, Hess OM, Losi MA, Nonogi H, Krayenbuehl HP: Regional left
ventricular mechanics in hypertrophic cardiomyopathy. Circulation 1993,
88:2206-14.
69. Ganame J, Mertens L, Eidem BW, Claus P, D’hooge J, Havemann LM,
McMahon CJ, Elayda MA, Vaughn WK, Towbin JA, Ayres NA, Pignatelli RH:
Regional myocardial deformation in children with hypertrophic
cardiomyopathy: morphological and clinical correlations. Eur Heart J
2007, 28(23):2886-94.
70. Weidemann F, Niemann M, Herrmann S, Kung M, Störk S, Waller C, Beer M,
Breunig F, Wanner C, Voelker W, Ertl G, Bijnens B, Strotmann JM: A new
echocardiographic approach for the detection of non-ischemic fibrosis
in hypertrophic myocardium. Eur Heart J 2007, 28:3020-6.
71. Notomi Y, Setser RM, Shiota T, Martin-Miklovic MG, Weaver JA, Popovic ZB,
Yamada H, Greenberg NL, White RD, Thomas JD: Assessment of left
ventricular torsional deformation by Doppler tissue imaging: a validation
study using tagged magnetic resonance imaging. Circulation 2005,
111:1141-1147.
72. Notomi Y, Martin-Miklovic MG, Oryszak SJ, Shiota T, Deserranno D,
Popovic ZB, Garcia MJ, Greenberg NL, Thomas JD: Enhanced ventricular
untwisting during exercise: a mechanistic manifestation of elastic recoil
described by Doppler tissue imaging. Circulation 2006, 113:2524-33.
73. Wang J, Buergler JM, Veerasamy K, Ashton YP, Nagueh SF: Delayed
untwisting: the mechanistic link between dynamic obstruction and
exercise tolerance in patients with hypertrophic obstructive
cardiomyopathy. J Am Coll Cardiol 2009, 54:1326-34.
74. Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, Thomas JD,
Merlino JD: Differentiation of hypertrophic cardiomyopathy and cardiac
amyloidosis from other causes of ventricular wall thickening by two-
dimensional strain imaging echocardiography. Am J Cardiol 2009,
103:411-5.
75. Lazzeroni E, Picano E, Morozzi L, Maurizio AR, Palma G, Ceriati R, Iori E,
Barilli A: Dipyridamole-induced ischemia as a prognostic marker of future
adverse cardiac events in adult patients with hypertrophic
cardiomyopathy. Echo Persantine Italian Cooperative (EPIC) Study Group,
Subproject Hypertrophic Cardiomyopathy. Circulation 1997, 96:4268-72.
76. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG: Coronary
microvascular dysfunction and prognosis in hypertrophic
cardiomyopathy. N Engl J Med 2003, 349:1027-35.
77. Cortigiani L, Rigo F, Gherardi S, Galderisi M, Sicari R, Picano E: Prognostic
implications of coronary flow reserve on left anterior descending
coronary artery in hypertrophic cardiomyopathy. Am J Cardiol 2008,
102:1718-23.
78. Maron MS: The current and emerging role of cardiovascular magnetic
resonance imaging in hypertrophic cardiomyopathy. J of Cardiovasc Trans
Res 2009, 2:415-25.
79. Romano R, Losi MA, Migliore T, Contaldi C, Parrella LS, Caputi A, Betocchi S:
Evaluation of the left ventricular anatomy in hypertrophic
cardiomyopathy: comparison between echocardiography and cardiac
magnetic resonance imaging. Minerva Cardioangiol 2008, 56:181-7.
80. Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, De Santis M,
Quarta G, Nistri S, Cecchi F, Salton CJ, Udelson JE, Manning WJ, Maron BJ:
Assessment and significance of left ventricular mass by cardiovascular
magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol
2008, 52:559-66.
81. Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, Weil J,
Zenovich AG, Maron BJ: Utility of cardiac magnetic resonance imaging in
the diagnosis of hypertrophic cardiomyopathy. Circulation 2005,
112:855-61.
82. Maron BJ, Moller JH, Seidman CE, Vincent GM, Dietz HC, Moss AJ,
Towbin JA, Sondheimer HM, Pyeritz RE, McGee G, Epstein AE: Impact of
laboratory molecular diagnosis on contemporary diagnostic criteria for
genetically transmitted cardiovascular diseases: hypertrophic
cardiomyopathy, Long-QT Syndrome, and Marfan Syndrome. Circulation
1998, 98:1460-1471.
83. Colombo MG, Botto N, Vittorini S, Paradossi U, Andreassi MG: Clinical utility
of genetic tests for inherited hypertrophic and dilated
cardiomyopathies. Cardiovasc Ultrasound 2008, 19:6-62.
doi:10.1186/1476-7120-8-7
Cite this article as: Losi et al.: Echocardiography in patients with
hypertrophic cardiomyopathy: usefulness of old and new techniques in
the diagnosis and pathophysiological assessment. Cardiovascular
Ultrasound 2010 8:7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Losi et al. Cardiovascular Ultrasound 2010, 8:7
http://www.cardiovascularultrasound.com/content/8/1/7
Page 19 of 19
